primary monoclonal rabbit anti-hent1 Search Results


anti-hent1 rabbit polyclonal antibody  (Abnova)
90
Abnova anti-hent1 rabbit polyclonal antibody
Anti Hent1 Rabbit Polyclonal Antibody, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+monoclonal+rabbit+anti-hent1/anti+hent1+rabbit+polyclonal+antibody+pab2255/pm28476815-86-12-16
Average 90 stars, based on 1 article reviews
anti-hent1 rabbit polyclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rabbit anti-hent-1 monoclonal antibody  (MBL International)
90
MBL International rabbit anti-hent-1 monoclonal antibody
Rabbit Anti Hent 1 Monoclonal Antibody, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+monoclonal+rabbit+anti-hent1/rabbit+sev+antibody/pmc05494679-135-7-11
Average 90 stars, based on 1 article reviews
rabbit anti-hent-1 monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hent1  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology hent1
Sclareolide upregulates <t>hENT1</t> and downregulates RRM1 in GR-HPCC, and enhances gemcitabine-induced GR-HPCC death through hENT1 and RRM1 signals. HPCC and GR-HPCC were treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. Sclareolide (A) recovered the suppression of the mRNA and protein expression levels of hENT1, and (B) recovered the activation of the mRNA and protein expression levels of RRM1 in the GR-HPCCs. (C) GR-Panc-1 cells were transfected with control siRNA or hENT1-siRNA, and treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. The cell death ratio was analyzed using Trypan blue. (D) GR-Panc-1 cells were transfected with the control plasmid (con-pcDNA3.1) or RRM1-plasmid (RRM1-pcDNA3.1), and treated with 1 µm gemcitabine with or without 10 µm sclareolide (2 h pretreatment) for 24 h. The cell death ratio was analyzed using Trypan blue. *P<0.05; **P<0.01 and ***P<0.005. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; siRNA, small interfering RNA.
Hent1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+monoclonal+rabbit+anti-hent1/EGF/pmc05365005-55-19-9
Average 93 stars, based on 1 article reviews
hent1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
anti hent1 mouse monoclonal antibody  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti hent1 mouse monoclonal antibody
Sclareolide upregulates <t>hENT1</t> and downregulates RRM1 in GR-HPCC, and enhances gemcitabine-induced GR-HPCC death through hENT1 and RRM1 signals. HPCC and GR-HPCC were treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. Sclareolide (A) recovered the suppression of the mRNA and protein expression levels of hENT1, and (B) recovered the activation of the mRNA and protein expression levels of RRM1 in the GR-HPCCs. (C) GR-Panc-1 cells were transfected with control siRNA or hENT1-siRNA, and treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. The cell death ratio was analyzed using Trypan blue. (D) GR-Panc-1 cells were transfected with the control plasmid (con-pcDNA3.1) or RRM1-plasmid (RRM1-pcDNA3.1), and treated with 1 µm gemcitabine with or without 10 µm sclareolide (2 h pretreatment) for 24 h. The cell death ratio was analyzed using Trypan blue. *P<0.05; **P<0.01 and ***P<0.005. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; siRNA, small interfering RNA.
Anti Hent1 Mouse Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+monoclonal+rabbit+anti-hent1/ENT1+Antibody/pm29275122-53-6-12
Average 93 stars, based on 1 article reviews
anti hent1 mouse monoclonal antibody - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Sclareolide upregulates hENT1 and downregulates RRM1 in GR-HPCC, and enhances gemcitabine-induced GR-HPCC death through hENT1 and RRM1 signals. HPCC and GR-HPCC were treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. Sclareolide (A) recovered the suppression of the mRNA and protein expression levels of hENT1, and (B) recovered the activation of the mRNA and protein expression levels of RRM1 in the GR-HPCCs. (C) GR-Panc-1 cells were transfected with control siRNA or hENT1-siRNA, and treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. The cell death ratio was analyzed using Trypan blue. (D) GR-Panc-1 cells were transfected with the control plasmid (con-pcDNA3.1) or RRM1-plasmid (RRM1-pcDNA3.1), and treated with 1 µm gemcitabine with or without 10 µm sclareolide (2 h pretreatment) for 24 h. The cell death ratio was analyzed using Trypan blue. *P<0.05; **P<0.01 and ***P<0.005. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; siRNA, small interfering RNA.

Journal: Molecular Medicine Reports

Article Title: Sclareolide enhances gemcitabine-induced cell death through mediating the NICD and Gli1 pathways in gemcitabine-resistant human pancreatic cancer

doi: 10.3892/mmr.2017.6182

Figure Lengend Snippet: Sclareolide upregulates hENT1 and downregulates RRM1 in GR-HPCC, and enhances gemcitabine-induced GR-HPCC death through hENT1 and RRM1 signals. HPCC and GR-HPCC were treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. Sclareolide (A) recovered the suppression of the mRNA and protein expression levels of hENT1, and (B) recovered the activation of the mRNA and protein expression levels of RRM1 in the GR-HPCCs. (C) GR-Panc-1 cells were transfected with control siRNA or hENT1-siRNA, and treated with 1 µm gemcitabine alone or co-treated with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. The cell death ratio was analyzed using Trypan blue. (D) GR-Panc-1 cells were transfected with the control plasmid (con-pcDNA3.1) or RRM1-plasmid (RRM1-pcDNA3.1), and treated with 1 µm gemcitabine with or without 10 µm sclareolide (2 h pretreatment) for 24 h. The cell death ratio was analyzed using Trypan blue. *P<0.05; **P<0.01 and ***P<0.005. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; siRNA, small interfering RNA.

Article Snippet: All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), the details of antibodies were followed: hENT1 (sc-48489, polyclonal, goats anti-human), GAPDH (sc-293335, monoclonal, mouse anti-human), RRM1 (sc-22786, monoclonal, rabbit anti-human), Twist1 (sc-134136, polyclonal, mouse anti-human), Slug (sc-166902, monoclonal, mouse anti-human), E-cadherin (sc-33743, polyclonal, rabbit anti-human), α-SMA (sc-53142, monoclonal, mouse anti-human), NICD (sc-74276, monoclonal, mouse anti-human), Gli1 (sc-20687, polyclonal, rabbit anti-human), PARP (sc-27034, polyclonal, goats anti-human), Capase3 (sc-1224, polyclonal, goats anti-human), goats IgG (sc-2419), mouse IgG (sc-516176), rabbit IgG (sc-2794).

Techniques: Expressing, Activation Assay, Transfection, Plasmid Preparation, Small Interfering RNA

Sclareolide suppresses the EMT phenotype of GR-HPCC through TWIST1 and Slug signals, and recovers the activation of TWIST1 and Slug in GR-HPCCs. HPCCs and GR-HPCCs were treated with 1 µm gemcitabine alone or with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. (A) Sclareolide recovered the activation of TWIST1 and Slug in GR-HPCCs. GR-Panc-1 cells were transfected with control siRNA, (B) TWIST1-siRNA or (C) Slug-siRNA, and expression levels of hENT, RRM1, α-SMA and E-cadherin were analyzed. Cell death ratios were analyzed in the (D) TWIST1-siRNA and (E) Slug-siRNA cells using Trypan blue. (F) Sclareolide suppressed the invasive ability of GR-HPCCs, HPCCs and GR-HPCCs treated with 1 µm gemcitabine alone or with 10 µm sclareolide (2 h pretreatment) for 24 h. Magnification, ×400. *P<0.05 and **P<0.01. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; α-SMA, α-smooth muscle actin; siRNA, small interfering RNA.

Journal: Molecular Medicine Reports

Article Title: Sclareolide enhances gemcitabine-induced cell death through mediating the NICD and Gli1 pathways in gemcitabine-resistant human pancreatic cancer

doi: 10.3892/mmr.2017.6182

Figure Lengend Snippet: Sclareolide suppresses the EMT phenotype of GR-HPCC through TWIST1 and Slug signals, and recovers the activation of TWIST1 and Slug in GR-HPCCs. HPCCs and GR-HPCCs were treated with 1 µm gemcitabine alone or with 10 µm sclareolide (2 h pretreatment) and 1 µm gemcitabine for 24 h. (A) Sclareolide recovered the activation of TWIST1 and Slug in GR-HPCCs. GR-Panc-1 cells were transfected with control siRNA, (B) TWIST1-siRNA or (C) Slug-siRNA, and expression levels of hENT, RRM1, α-SMA and E-cadherin were analyzed. Cell death ratios were analyzed in the (D) TWIST1-siRNA and (E) Slug-siRNA cells using Trypan blue. (F) Sclareolide suppressed the invasive ability of GR-HPCCs, HPCCs and GR-HPCCs treated with 1 µm gemcitabine alone or with 10 µm sclareolide (2 h pretreatment) for 24 h. Magnification, ×400. *P<0.05 and **P<0.01. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; α-SMA, α-smooth muscle actin; siRNA, small interfering RNA.

Article Snippet: All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), the details of antibodies were followed: hENT1 (sc-48489, polyclonal, goats anti-human), GAPDH (sc-293335, monoclonal, mouse anti-human), RRM1 (sc-22786, monoclonal, rabbit anti-human), Twist1 (sc-134136, polyclonal, mouse anti-human), Slug (sc-166902, monoclonal, mouse anti-human), E-cadherin (sc-33743, polyclonal, rabbit anti-human), α-SMA (sc-53142, monoclonal, mouse anti-human), NICD (sc-74276, monoclonal, mouse anti-human), Gli1 (sc-20687, polyclonal, rabbit anti-human), PARP (sc-27034, polyclonal, goats anti-human), Capase3 (sc-1224, polyclonal, goats anti-human), goats IgG (sc-2419), mouse IgG (sc-516176), rabbit IgG (sc-2794).

Techniques: Activation Assay, Transfection, Expressing, Small Interfering RNA

Sclareolide pathway enhances gemcitabine-induced gemcitabine-resistant human pancreatic cancer cell death. HPCCs became GR-HPCCs due to the activation of NICD and Gli1. Inhibition of hENT1 and activation of RRM1 contributed to gemcitabine resistance. NICD and Gli1 can activated TWIST1 and Slug, which contributed to EMT. Sclareolide inhibited these alterations. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; NICDl, NOTCH1 intracellular cytoplasmic domain; Gli1, glioma-associated oncogene 1; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; EMT, epithelial to mesenchymal transition.

Journal: Molecular Medicine Reports

Article Title: Sclareolide enhances gemcitabine-induced cell death through mediating the NICD and Gli1 pathways in gemcitabine-resistant human pancreatic cancer

doi: 10.3892/mmr.2017.6182

Figure Lengend Snippet: Sclareolide pathway enhances gemcitabine-induced gemcitabine-resistant human pancreatic cancer cell death. HPCCs became GR-HPCCs due to the activation of NICD and Gli1. Inhibition of hENT1 and activation of RRM1 contributed to gemcitabine resistance. NICD and Gli1 can activated TWIST1 and Slug, which contributed to EMT. Sclareolide inhibited these alterations. GR-HPCCs, gemcitabine-resistant human pancreatic cancer cells; NICDl, NOTCH1 intracellular cytoplasmic domain; Gli1, glioma-associated oncogene 1; hENT1, human equilibrative nucleoside transporter 1; RRM1, ribonucleoside diphosphate reductase 1; EMT, epithelial to mesenchymal transition.

Article Snippet: All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), the details of antibodies were followed: hENT1 (sc-48489, polyclonal, goats anti-human), GAPDH (sc-293335, monoclonal, mouse anti-human), RRM1 (sc-22786, monoclonal, rabbit anti-human), Twist1 (sc-134136, polyclonal, mouse anti-human), Slug (sc-166902, monoclonal, mouse anti-human), E-cadherin (sc-33743, polyclonal, rabbit anti-human), α-SMA (sc-53142, monoclonal, mouse anti-human), NICD (sc-74276, monoclonal, mouse anti-human), Gli1 (sc-20687, polyclonal, rabbit anti-human), PARP (sc-27034, polyclonal, goats anti-human), Capase3 (sc-1224, polyclonal, goats anti-human), goats IgG (sc-2419), mouse IgG (sc-516176), rabbit IgG (sc-2794).

Techniques: Activation Assay, Inhibition